Having trouble accessing articles? Reset your cache.

Tarceva-Avastin combo meets endpoint

Genentech (NYSE:DNA) said a DSMB recommended ending the Phase IIIb ATLAS trial for first-line treatment of non-small cell

Read the full 189 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE